CTIM-02. PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS – ANALYSIS FROM THE INITIAL PATIENTS TREATED ON THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04
Rebecca Ronsley(Seattle Children's Hospital), Nicholas A. Vitanza(Seattle Children's Hospital), Sowmya Pattabhi, Jason S. Hauptman(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Erin Crotty(Seattle Children's Hospital), Sarah Leary(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Daniel V. Runco(Seattle Children's Hospital), Wenjun Huang(Lishui Central Hospital), Jason Wendler(Pacific Northwest National Laboratory), Prabha Narayanaswamy, Rebecca Gardner(Seattle Children's Hospital), Kristy Seidel(Fred Hutch Cancer Center), Colleen Annesley(Unknown), Juliane Gust(University of Washington), On Ho, Michael C. Jensen(Seattle Children's Hospital)
Cited by 2
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k